Tenofovir alafenamide

Tenofovir alafenamide has been studied in 12 papers since 2022: 2 trials and 3 observational studies in people, 2 in animals, 2 in cells, 3 reviews; 7 in the past year. It is an approved medicine. The newest paper, Nov 18, 2026: “Longitudinal changes in the odds of metabolic syndrome among people living with HIV receiving dolutegravir-, tenofovir alafenamide-, or…”.

InterventionApproved 2016

12 papers study it3 more mention it6 findingsUpdated

PubChemChEBIMeSH

1 new paper in 30 daysSee all 15 papers on tenofovir alafenamide

At a glance

The findings reach people, from one lab or study. 5 independent labs in 4 countries; 88 trials, none about aging, 20 with no results posted.

“We demonstrated a trend to increased BMD at the lumbar spine after a switch from TDF to TAF in peri- and early postmenopausal women living with HIV.”
BEING: Bone Health in Aging Women with HIV: Impact of Switching Antiretroviral Therapy on Bone Mineral Density During the Perimenopausal PeriodAIDS research and human retroviruses2022doi:10.1089/aid.2022.0106

None of its findings points the other way.

Cells and humans: a single group. Worms or flies and mice: nothing yet.
  • 5 independent labs in 4 countries
  • 88 trials, none about aging, 20 with no results posted
  • Funder: Korean Association for the Study of the Liver
  • Human trial2
  • Humans3
  • Animals2
  • Cells2

Studies in people

1 study gave tenofovir alafenamide to people and measured what changed.

What changedDesignPeopleSource

up: Increases bone mineral density1.97% (-1.15 to 5.49) vs -2.32% (-5.11 to 0.19)

Randomized trial48 weeks34 peopleWomenmedian 51 yearsMidlife adults; Postmenopausal women; peri- and early postmenopausal women living with HIVAIDS research and human retroviruses, Dec 14, 2022

What did studies of tenofovir alafenamide find?

4

Studies of tenofovir alafenamide measured 4 outcomes, among them MYOD1, cellular senescence and bone mineral density.

MYOD1

downin human cells1

1 study
  1. Tenofovir alafenamide decreases MYOD1 in primary human mesenchymal stem cells and myoblasts.

    “Moreover, FTC and TAF decreased expression of myoblast differentiation markers (MYOG and MYOD).”

    Cellsin primary human mesenchymal stem cells and myoblasts

    THE AHR AS A POTENTIAL MEDIATOR OF MUSCULOSKELETAL FRAILTY WITH ANTI-RETROVIRAL THERAPY

    GSA 2024 abstract

More on MYOD1

Cellular senescence

upin human cells1

1 study
  1. Tenofovir alafenamide increases cellular senescence in primary human mesenchymal stem cells and myoblasts.

    “showing increased expression of AhR, AhR target genes, and increased senescence in both cell populations.”

    Cellsin primary human mesenchymal stem cells and myoblasts

    THE AHR AS A POTENTIAL MEDIATOR OF MUSCULOSKELETAL FRAILTY WITH ANTI-RETROVIRAL THERAPY

    GSA 2024 abstract

More on Cellular senescence

Bone mineral density

upin humans1

1 study
  1. Tenofovir alafenamide increases bone mineral density in humans (peri- and early postmenopausal women living with HIV) (1.97% (-1.15 to 5.49) vs -2.32% (-5.11 to 0.19)).

    “We demonstrated a trend to increased BMD at the lumbar spine after a switch from TDF to TAF in peri- and early postmenopausal women living with HIV.”

    Human trialperi- and early postmenopausal women living with HIVlumbar spine48 weeksfemalesn = 34

    BEING: Bone Health in Aging Women with HIV: Impact of Switching Antiretroviral Therapy on Bone Mineral Density During the Perimenopausal Period

    AIDS research and human retroviruses

More on Bone mineral density

Skeletal muscle mass

upin humans1

1 study
  1. Tenofovir alafenamide is linked with higher skeletal muscle mass in humans (people living with HIV).

    “The tenofovir alafenamide (TAF) use group had significantly higher BMI, higher skeletal muscle mass, body fat mass, and skeletal muscle mass index relative to the non-TAF use group.”

    Humanspeople living with HIVmalesn = 87

    Sarcopenia among people living with HIV and the effect of antiretroviral therapy on body composition

    Medicine

What is tenofovir alafenamide linked with?

2

Studies link tenofovir alafenamide with 2 measures: atherosclerotic cardiovascular disease and osteoporotic fractures.

Atherosclerotic cardiovascular disease

downin humans1HR 0.7

1 study
  1. Tenofovir alafenamide is linked with a lower risk of atherosclerotic cardiovascular disease in humans after PS matching (HR 0.70, p < 0.001).

    “TAF was associated with lower ASCVD risk than TDF (4.60 vs. 6.88/1000 PYs; p < 0.001), a trend maintained after PS matching (4.67 vs. 6.67/1000 PYs; hazard ratio 0.70; p < 0.001)”

    Humansafter PS matching

    Atherosclerotic Cardiovascular Risk in Patients with Chronic Hepatitis B: Tenofovir Disoproxil Fumarate Vs. Tenofovir Alafenamide: A Korean Nationwide Study

    Journal of medical virology

More on Atherosclerotic cardiovascular disease

Osteoporotic fractures

downin humans1HR 0.68

1 study
  1. Tenofovir alafenamide is associated with osteoporotic fractures in humans (HR 0.68, 95% CI 0.55–0.85; 0.49 versus 0.78 fractures per 100 person-years).

    “TAF-treated patients with CHB had a significantly lower risk of osteoporotic fracture than TDF-treated patients.”

    HumansChronic hepatitis B; compared with tenofovir disoproxil fumarate, after inverse probability treatment weighting24.4 ± 11.6 months64.5% mensn = 32,582

    Tenofovir disoproxil fumarate versus tenofovir alafenamide on risk of osteoporotic fracture in patients with chronic hepatitis B: A nationwide claims study in South Korea

    Alimentary pharmacology & therapeutics

More on Osteoporotic fractures

Has tenofovir alafenamide been tested in people?

0 of 88 about aging

Yes: 2 trials and 3 observational studies in people have been published, and 88 trials are registered.

Approved

  • FDA Vemlidy

    Nov 10, 2016Hepatitis B Virus, Hepatitis B, Chronic, Hepatitis B Virus Infection, chronic hepatitis B virus infection

  • EMA Vemlidy

    Jan 9, 2017Hepatitis B, Chronic Hepatitis B in Adults and Paediatric Patients

Repurposing

All 22

In trials

  • Hbv

    Phase 4Status unknown3 trials

  • HIV Prevention

    Phase 4Completed2 trials

  • Human immunodeficiency virus i infection

    Phase 4Status unknown1 trial

  • Lentivirus infection

    Phase 4Recruiting1 trial

  • B-cell leukemia

    Phase 2Terminated1 trial

  • Chronic hepatitis D

    Phase 2Results posted1 trial

All 10

Stopped

  • NCT03804372TerminatedB-cell leukemia

    low enrollment rate

Who is developing tenofovir alafenamide?

3 companies: Merck Sharp & Dohme, Humanis Saglık Anonim Sirketi and Janssen Research & Development.

Companies
  • Merck Sharp & DohmePhase 1
  • Humanis Saglık Anonim SirketiPhase 1Chronic Hepatitis B in Adults and Paediatric Patients
  • Janssen Research & DevelopmentPhase 1

Trial sponsors

Latest

Dec 2025: 3Jan 2026: 0Feb 2026: 2Mar 2026: 1Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 1Nov 2026: 18 papers in 12 months

See all 15 papers on tenofovir alafenamide